

1 XAVIER BECERRA
 Attorney General of California
 2 MONICA N. ANDERSON
 Senior Assistant Attorney General
 3 ADRIANO HRVATIN
 Supervising Deputy Attorney General
 4 ELISE OWENS THORN, State Bar No. 145931
 TYLER V. HEATH, State Bar No. 271478
 5 KYLE A. LEWIS, State Bar No. 201041
 LUCAS HENNES, State Bar No. 278361
 6 Deputy Attorneys General
 1300 I Street, Suite 125
 7 P.O. Box 944255
 Sacramento, CA 94244-2550
 8 Telephone: (916) 210-7325
 Fax: (916) 324-5205
 9 E-mail: Tyler.Heath@doj.ca.gov
Attorneys for Defendants

ROMAN M. SILBERFELD, State Bar No. 62783
 GLENN A. DANAS, State Bar No. 270317
 ROBINS KAPLAN LLP
 2049 Century Park East, Suite 3400
 Los Angeles, CA 90067-3208
 Telephone: (310) 552-0130
 Fax: (310) 229-5800
 E-mail: RSilberfeld@RobinsKaplan.com
Special Counsel for Defendants

11 IN THE UNITED STATES DISTRICT COURT
 12 FOR THE EASTERN DISTRICT OF CALIFORNIA
 13 SACRAMENTO DIVISION

15 **RALPH COLEMAN, et al.,**

16 Plaintiffs,

17 v.

19 **GAVIN NEWSOM, et al.,**

20 Defendants.

2:90-cv-00520 KJM-DB (PC)

**DECLARATION J. BICK, M.D. IN
 SUPPORT OF DEFENDANTS'
 RESPONSE TO ORDER TO SHOW
 CAUSE**

22 I, J. Bick, M.D., declare:

23 1. I am currently the Director of Health Care Services for the California Department
 24 of Corrections and Rehabilitation (CDCR). In this capacity, I oversee the mental health and
 25 dental programs providing services to CDCR's inmate patients. Before holding this position, I
 26 served as the Chief Medical Executive at CDCR's California Medical Facility from 2010-2020,
 27 the facility's Chief Deputy for Clinical Services from 2007-2010, and the facility's Chief Medical
 28 Officer from 1994-2007. I submit this declaration in support of Defendants' Response to Order

1 to Show Cause.

2 2. I received a Medical Doctorate from the University of Michigan Medical School in
3 1987, and am a board certified internist and infectious diseases specialist. I completed an
4 infectious diseases fellowship at St. Luke's Medical Center in Chicago, Illinois in 1993, and am a
5 Fellow in the Infectious Diseases Society of America. In addition to my work at CDCR, I have
6 served as a Visiting Associate Professor for Infectious Diseases at the University of Malaya
7 Medical Centre, Kuala Lumpur, Malaysia from 2012-2013; an International Technical Expert on
8 Prisons with the United Nations Office for Project Services, Myanmar from 2013-2014; an
9 Infectious Diseases Consultant for Kajang Prison in Kajang, Malaysia from 2012-2016; and a
10 Court-Appointed Medical Monitor in *Leatherwood, et al. v. Campbell, et al.*, No. CV-02-BE-
11 2812-W (W.D. Ala.), a class action concerning human immunodeficiency virus (HIV) infected
12 prisoners in the Alabama Department of Corrections, from 2005-2007. I have contributed to
13 various publications addressing infectious diseases in the correctional setting, and was the
14 Assistant Editor of the "Infectious Diseases in Corrections Report" from 1997-2008, and have
15 lectured on infectious diseases including Mycobacterium Tuberculosis, Hepatitis C, Methicillin
16 Resistant Staphylococcus aureus, Coccidioidomycosis (Valley fever), and HIV.

17 3. Coronavirus disease 2019 (COVID-19) is a respiratory illness caused by a novel
18 (new) coronavirus. According to the Centers for Disease Control and Prevention (CDC), the
19 virus that causes COVID-19 is spread by both respiratory and person-to-person contact.
20 (<https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/how-covid-spreads.html>, last
21 retrieved April 6, 2020.) Persons infected by the coronavirus have experienced symptoms
22 including fever, cough, and shortness of breath, which can appear 2-14 days after exposure.
23 (<https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>, last retrieved
24 April 6, 2020.) Infected persons may feel a range of illness, from mild symptomology to more
25 severe illness that can cause death. Other infected persons can also be asymptomatic after
26 exposure. According to Dr. Anthony Fauci, director of the National Institute of Allergy and
27 Infectious Diseases, the number of asymptomatic cases could be "somewhere between 25 and
28 50%." (<https://www.health.com/condition/infectious-diseases/coronavirus/asymptomatic->

1 carriers-coronavirus, last retrieved April 6, 2020.) These viremic but asymptomatic individuals
2 can transmit coronavirus to other persons even though they have no symptoms of infection,
3 making it incredibly difficult for health care providers to screen them in the absence of instant
4 testing, while posing high infections risk to populations with whom such asymptomatic
5 individuals intermix.

6 4. COVID-19 poses a particular risk in confined settings, such as controlled patient
7 facilities and correctional institutions, given the proximity of patients or inmates to one another
8 and the ease with which the virus can be transmitted through a confined population. The CDC
9 advises that some ways to prevent COVID-19 from entering a correctional facility from the
10 community are to limit non-medical transfers in and out of the facility and screen all new
11 entrants, staff, and visitors prior to entering the facility. ([https://www.cdc.gov/coronavirus/2019-
12 ncov/community/correction-detention/index.html](https://www.cdc.gov/coronavirus/2019-ncov/community/correction-detention/index.html), last retrieved April 6, 2020.) Because the
13 greatest danger of exposure to these enclosed communities is by introduction of the virus from
14 external sources, I believe that, in addition to robust staff screening, it is paramount to limit the
15 movement of patients and inmates between such facilities. Limitation of movement to that which
16 is absolutely essential is key to limiting the spread of this virus.

17 5. Under a Memorandum of Understanding and related agreed-to procedures between
18 CDCR and the Department of State Hospitals (DSH), certain CDCR inmate-patients in the
19 Mental Health Services Delivery System who are both clinically and custodially eligible can be
20 admitted to DSH facilities to receive intermediate-level mental health care. On March 16, 2020,
21 to reduce the possible introduction of COVID-19 into its facilities, DSH temporarily suspended
22 admissions of certain patient groups, including CDCR patients. Since the admission suspension
23 commenced, I have been in regular contact with Dr. Katherine Warburton, DSH Medical
24 Director, concerning DSH's response to the pandemic and potential availability of DSH inpatient
25 resources for CDCR patients. I agree with Dr. Warburton's concerns regarding the importance of
26 limiting patient admissions to prevent the introduction of COVID-19 into DSH facilities. Dr.
27 Warburton and I have discussed conditions under which a CDCR patient who satisfied certain
28 criteria could be evaluated for admission to DSH if absolutely necessary to provide mental health

1 treatment, and are jointly developing a COVID-19 screening protocol that would be one of the
2 tools that can assist both Departments in evaluating the propriety of a transfer between our two
3 systems. Such evaluations would take place on a case-by-case basis, and, if a transfer to DSH
4 was deemed absolutely necessary from a clinical perspective, all movement should be
5 accompanied by a thorough clinical screening to reduce the risk of COVID-19 introduction to a
6 DSH facility.

7 6. Based on my conversations with Dr. Warburton, I understand that DSH has reduced
8 movement throughout its facilities to prevent the introduction or spread of COVID-19. For
9 similar reasons, CDCR officials have also taken actions to curtail all non-emergency movement.
10 Recognizing the need to continue providing mental health services to its patients, CDCR mental
11 health staff have worked with the *Coleman* Special Master and his experts to develop temporary
12 transfer guidelines and processes for clinicians to refer patients for various levels of mental health
13 inpatient care. Although still in development, these guidelines seek to minimize, where possible,
14 patient movement outside of their present institution and are consistent with prevailing medical
15 opinions concerning mitigation of COVID-19 introduction risk through reduced inter-institution
16 transfers.

17 I declare under penalty of perjury that to the best of my knowledge the above is true and
18 correct. Executed on this 8th day of April, 2020, at Davis, California.

19
20 /s/ J. Bick

21 J. Bick, M.D.

22 *Original Signature Retained by Attorney*

23 CF1997CS0003
24
25
26
27
28